# Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia

> **NCT04519125** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hospital Universitario San Ignacio** · enrollment: 950 (estimated)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2
- COVID-19

## Interventions

- **DRUG:** Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
- **OTHER:** Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)

## Key facts

- **NCT ID:** NCT04519125
- **Lead sponsor:** Hospital Universitario San Ignacio
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-30
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-04-01
- **Target enrollment:** 950 (ESTIMATED)
- **Last updated:** 2020-08-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519125, "Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04519125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*